Read by QxMD icon Read

Famotidine schizophrenia

Ricardo P Garay, Ludovic Samalin, Ahcène Hameg, Pierre-Michel Llorca
INTRODUCTION: Anxiety is a frequent symptom of schizophrenia, which is highly associated with an increased risk of relapse and suicide. The effect of antipsychotics on this clinical dimension is not specific and the common practice of prescribing benzodiazepines remains unsatisfactory. AREAS COVERED: The authors review recent well-designed clinical trials for anxiety in patients with schizophrenia. The content includes information derived from trial databases, regulatory authorities and scientific literature...
April 2015: Expert Opinion on Investigational Drugs
Chittaranjan Andrade
No abstract text is available yet for this article.
September 2013: Journal of Clinical Psychiatry
Katarina Meskanen, Heidi Ekelund, Jarmo Laitinen, Pertti J Neuvonen, Jari Haukka, Pertti Panula, Jesper Ekelund
Histamine has important functions as regulator of several other key neurotransmitters. Patients with schizophrenia have lower histamine H1 receptor levels. Since a case report in 1990 of an effect of the H2 antagonist famotidine on negative symptoms in schizophrenia, some open-label trials have been performed, but no randomized controlled trial. Recently, it was shown that clozapine is a full inverse agonist at the H2 receptor. We performed a researcher-initiated, academically financed, double-blind, placebo-controlled, parallel-group, randomized trial with the histamine H2 antagonist famotidine in treatment-resistant schizophrenia...
August 2013: Journal of Clinical Psychopharmacology
Michael Poyurovsky, Vered Tal, Rachel Maayan, Irit Gil-Ad, Camil Fuchs, Abraham Weizman
Olanzapine treatment is associated with substantial weight gain. In this double-blind placebo-controlled study we evaluated whether the H2 antagonist famotidine may prevent/attenuate olanzapine-induced weight gain. Fourteen first-episode DSM-IV schizophrenia patients were randomly allocated to receive either famotidine (40 mg/day, n=7) or placebo (n=7) in addition to olanzapine (10 mg/day) for 6 weeks. All patients completed the trial. Patients in both groups showed a similar increase in body weight (olanzapine/famotidine: 4...
August 2004: European Neuropsychopharmacology: the Journal of the European College of Neuropsychopharmacology
M C Martinez
OBJECTIVE: To evaluate the use and potential benefit of famotidine in the management of schizophrenia. DATA SOURCES: Clinical literature accessed through MEDLINE (February 1998-October 1998). Key search terms included famotidine, schizophrenia, and histamine. DATA SYNTHESIS: Schizophrenia is a complicated disorder associated with high morbidity if left unmanaged. Histamine2 (H2)-antagonists may be an alternative to conventional treatments...
June 1999: Annals of Pharmacotherapy
S I Deutsch, R B Rosse, K A Kendrick, M Fay-McCarthy, J P Collins, R J Wyatt
The usefulness of the histamine-2 (H2) antagonist famotidine as an adjunct to conventional antipsychotic treatments of idiopathic psychotic disorders (i.e., schizophrenia and schizoaffective disorder) was investigated in an open-label study. After stabilization for at least 1 week with their conventional antipsychotic medication regimen, 10 patients completed a 3-week study period in which famotidine (20 mg twice a day) was added as an adjunctive medication. The 10 patients were all somewhat treatment refractory and had spent a mean of 230 days of the previous 2 years in the hospital...
December 1993: Clinical Neuropharmacology
L A Linday
Famotidine (Pepcid, a histamine-2 receptor blocker, is marketed for the treatment of peptic ulcer disease, gastroesophageal reflux, and the treatment of pathological hypersecretory conditions, including the Zollinger-Ellison syndrome. Recent reports indicate that it is also effective in relieving the deficit (or withdrawal) symptoms of adults with schizophrenia. Autism, a neuropsychiatric disorder which presents within the first few years of life, is defined by deficient social interaction, communication, language, play, and a markedly restricted repertoire of activities and interests...
May 1997: Medical Hypotheses
R B Rosse, K Kendrick, M Fay-McCarthy, G D Prell, P Rosenberg, L C Tsui, R J Wyatt, S I Deutsch
Histaminergic projections innervate brain areas implicated in the pathophysiology of schizophrenia. In a previous open-label study, there was the suggestion that famotidine, and H2 histamine-receptor antagonist, possessed adjuvant therapeutic properties when added to the stable neuroleptic medications regimens of 10 treatment-refractory patients. In that study, the maximal dosage of famotidine was limited to 40 mg/day, the recommended maximal dosage for the treatment of peptic ulcer disease. In this study, we examined 18 patients fulfilling DSM-III-R criteria for schizophrenia and schizoaffective disorder who had famotidine (100 mg/day) added to their stable neuroleptic medication regimen...
August 1996: Clinical Neuropharmacology
P B Rosenberg, R B Rosse, S K Johri, K Kendrick, M Fay-McCarthy, J P Collins, L C Tsui, R J Wyatt, S I Deutsch
Smooth pursuit eye movements (SPEM) are often abnormal in schizophrenic patients and have been proposed as a trait marker of the disorder. We explored the use of SPEM as an outcome measure in an open-label clinical trial of famotidine, an H-2 antagonist, in patients with schizophrenia; famotidine has been proposed as an adjunctive medication, particularly for negative symptoms. Prior studies using SPEM as an outcome measure have not found a significant effect with "typical" neuroleptic medication, and one study found greater SPEM dysfunction with clozapine treatment...
June 1996: Clinical Neuropharmacology
R B Rosse, K Kendrick, L C Tsui, M Fay-McCarthy, J P Collins, P Rosenberg, R J Wyatt, S I Deutsch
Recent reports suggest some utility for famotidine, a histamine type 2 (H2) antagonist, in the treatment of schizophrenia. The current report describes a treatment-resistant patient with chronic undifferentiated schizophrenia whose most dramatic symptomatic improvements were temporarily related to the open-label addition of famotidine (40-100 mg/day) to conventional neuroleptic treatment (molindone 150-200 mg/day) over the course of approximately 10 months. During one 2-week interval, his symptoms were controlled with famotidine (40 mg/day) alone...
August 1995: Clinical Neuropharmacology
L K Oyewumi, D Vollick, H Merskey, C Plumb
Some patients suffering from schizophrenia fail to respond to or tolerate adequate doses of available antipsychotic medications. Thus, innovative pharmacotherapeutic approaches, such as augmentation strategies, play an important role in the management of these treatment-resistant patients. A recent case report suggested that the administration of famotidine to a patient suffering from schizophrenia with peptic ulcer disease was associated with improvement in the deficit symptoms of schizophrenia. Famotidine is a potent highly selective H2 receptor antagonist which crosses the blood-brain barrier...
March 1994: Journal of Psychiatry & Neuroscience: JPN
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"